Sugi Predict

Sugi Predict / Compounds / SCHEMBL3763384

SCHEMBL3763384

SCHEMBL3763384

CN(CC(=O)O)c1ccc(C(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ TSHR P16473 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ RXRA P19793 1/20 0.44
▸ RXRB P28702 1/20 0.44
▸ RXRG P48443 1/20 0.44
▸ SRD5A2 P31213 2/20 0.43
▸ HPGD P15428 3/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CA1 P00915 3/20 0.41
▸ CA2 P00918 3/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA3 P07451 1/20 0.41
▸ TYR P14679 1/20 0.41
▸ DRD1 P21728 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10906215 0.88 ALDH1A1 (0.57) NPC1MEN1KMT2AALDH1A1SRD5A2
SCHEMBL4322658 0.86 MAPT (0.49) NPC1MEN1POLBKMT2AALDH1A1
SCHEMBL8372731 0.82 TSHR (0.53) NPC1MEN1POLBKMT2ATSHR
SCHEMBL797850 0.82 CA2 (0.43) ALDH1A1CA1CA2CA12CA3
SCHEMBL3348892 0.82 KEAP1 (0.54) KMT2ATSHRALDH1A1SMN1; SMN2CA1
SCHEMBL1784560 0.82 ALDH1A1 (0.52) NPC1MEN1POLBKMT2ATSHR
SCHEMBL196635 0.81 KMT2A (0.49) NPC1MEN1POLBKMT2ATSHR
SCHEMBL5726224 0.80 TDP1 (0.46) POLBTSHRTP53ALDH1A1SMN1; SMN2
SCHEMBL9632043 0.80 TPMT (0.40) MEN1KMT2AALDH1A1CA1CA2
SCHEMBL14364107 0.80 SLC6A9 (0.40) ALDH1A1SMN1; SMN2CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023196234-A1 METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES GLAZIER ALAN NEIL (US) 2023-10-12 — — WO claimed
EP-1370240-A4 NEUROPROTECTANTS FORMULATIONS AND METHODS NEURON THERAPEUTICS INC (US) 2004-09-22 — — EP claimed
EP-1392363-A2 COMPOSITIONS AND USES OF MGLUR5 ANTAGONISTS BROWN UNIVERSITY RESEARCH FOUNDATION (US) 2004-03-03 — — EP claimed
EP-1370240-A1 NEUROPROTECTANTS FORMULATIONS AND METHODS Neuron Therapeutics, Inc. (US) 2003-12-17 — — EP claimed
WO-2002078745-A2 USE OF MGLUR5 ANTAGONISTS IN THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF AUTISM, MENTAL RETARDATION, SCHIZOPHRENIA BROWN UNIVERSITY RESEARCH FOUNDATION (US) 2002-10-10 — — WO claimed
WO-2002078670-A1 NEUROPROTECTANTS FORMULATIONS AND METHODS NEURON THERAPEUTICS, INC. (US) 2002-10-10 — — WO claimed
US-20240408042-A1 ORALLY DISINTEGRATING BACLOFEN COMPOSITIONS AND METHODS OF MAKING SAME CLINICAL RES ASSOCIATES LLC (US) 2024-12-12 — — US disclosed
EP-2694504-A2 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER Afraxis Holdings, Inc. (US) 2014-02-12 — — EP disclosed
EP-2580216-A2 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS Afraxis, Inc. (US) 2013-04-17 — — EP disclosed
EP-2580213-A2 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS Afraxis, Inc. (US) 2013-04-17 — — EP disclosed
EP-2580217-A2 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS Afraxis, Inc. (US) 2013-04-17 — — EP disclosed
EP-2580215-A2 8-(2'-HETEROCYCYL)PYRIDO[2.3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS Afraxis, Inc. (US) 2013-04-17 — — EP disclosed
EP-2580214-A2 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS Afraxis, Inc. (US) 2013-04-17 — — EP disclosed
US-5587509-A Caged caboxyl compounds and use thereof CORNELL RESEARCH FOUNDATION, INC. (US) 1996-12-24 — — US disclosed
US-5536721-A Thieno[2,3-b-indole derivatives and their use for treating central nervous system diseases related to the metabotropic glutamate receptor system NOVO NORDISK A/S (DK) 1996-07-16 — — US disclosed
WO-1996015099-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1996-05-23 — — WO disclosed
WO-1996015100-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1996-05-23 — — WO disclosed
WO-1996005818-A1 METHODS AND COMPOUNDS ACTIVE AT METABOTROPIC GLUTAMATE RECEPTORS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES NPS PHARMACEUTICALS, INC. (US) 1996-02-29 — — WO disclosed
WO-1995025110-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1995-09-21 — — WO disclosed
US-5430175-A Caged carboxyl compounds and use thereof CORNELL RESEARCH FOUNDATION, INC. (US) 1995-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240408042-A1 ORALLY DISINTEGRATING BACLOFEN COMPOSITIONS AND METHODS OF MAKING SAME GABBR2, GABBR1, GABRB2 NPC1 2848/4885MEN1 1091/4885POLB 2970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.